Plasminogen activators are involved in angiostatin generation in vivo in benign and malignant ovarian tumor cyst fluids

International Journal of Oncology

Volumn 44, Issue 4, 2014, Pages 1394-1400

  Van Tilborg, A A G ^a   Sweep, F C G J ^a   Geurts Moespot, A J ^a   Wetzels, A M M ^a   De Waal, R M W ^a   Westphal, J R ^a   Massuger, L F A G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Angiogenesis; Angiostatin; Endometriosis; Ovarian tumor; Plasminogen activator

Indexed keywords

ANGIOSTATIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

BIOSYNTHESIS; CYST FLUID; ENDOMETRIOSIS; FEMALE; HUMAN; METABOLISM; OVARY CYST; OVARY FOLLICLE; OVARY TUMOR; PATHOLOGY; TERATOMA;

ANGIOSTATINS; CYST FLUID; DERMOID CYST; ENDOMETRIOSIS; FEMALE; HUMANS; OVARIAN CYSTS; OVARIAN FOLLICLE; OVARIAN NEOPLASMS; PLASMINOGEN; PLASMINOGEN ACTIVATORS; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84894468934     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2303     Document Type: Article

References (34)

1. Folkman J: Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 333: 1757-1763, 1995.
2. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995.
3. Carmeliet P and Collen D: Molecular analysis of blood vessel formation and disease. Am J Physiol 273: H2091-H2104, 1997.
4. Iruela-Arispe ML and Dvorak HF: Angiogenesis: a dynamic balance of stimulators and inhibitors. Thromb Haemost 78: 672-677, 1997. (Pubitemid 27289325)
5. Talks KL and Harris AL: Current status of antiangiogenic factors. Br J Haematol 109: 477-489, 2000. (Pubitemid 30415170)
6. Bicknell R and Harris AL: Mechanisms and therapeutic implications of angiogenesis. Curr Opin Oncol 8: 60-65, 1996. (Pubitemid 26093744)
7. Liekens S, De Clercq E and Neyts J: Angiogenesis: regulators and clinical applications. Biochem Pharmacol 61: 253-270, 2001. (Pubitemid 32126663)
8. Hofmann UB, Westphal JR, Van Muijen GN and Ruiter DJ: Matrix metalloproteinases in human melanoma. J Invest Dermatol 115: 337-344, 2000.
9. Pozzi A, Moberg PE, Miles LA, Wagner S, Soloway P and Gardner HA: Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. Proc Natl Acad Sci USA 97: 2202-2207, 2000. (Pubitemid 30134046)
10. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA and Cheresh DA: Definition of two angiogenic pathways by distinct alpha v integrins. Science 270: 1500-1502, 1995. (Pubitemid 3005294)
11. Brooks PC, Clark RA and Cheresh DA: Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264: 569-571, 1994.
12. O'Reilly MS, Holmgren L, Shing Y, et al: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328, 1994. (Pubitemid 24324921)
13. O'Reilly MS, Boehm T, Shing Y, et al: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285, 1997. (Pubitemid 28015876)
14. Holmgren L, O'Reilly MS and Folkman J: Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1: 149-153, 1995.
15. O'Reilly MS, Holmgren L, Chen C and Folkman J: Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2: 689-692, 1996. (Pubitemid 26191958)
16. Gately S, Twardowski P, Stack MS, et al: The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci USA 94: 10868-10872, 1997. (Pubitemid 27430827)
17. Westphal JR, Van't Hullenaar R, Geurts-Moespot A, et al: Angiostatin generation by human tumor cell lines: involvement of plasminogen activators. Int J Cancer 86: 760-767, 2000. (Pubitemid 30350189)
18. Cornelius LA, Nehring LC, Harding E, et al: Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol 161: 6845-6852, 1998. (Pubitemid 28562229)
19. Dong Z, Kumar R, Yang X and Fidler IJ: Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 88: 801-810, 1997. (Pubitemid 27164268)
20. Heidtmann HH, Nettelbeck DM, Mingels A, Jager R, Welker HG and Kontermann RE: Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen. Br J Cancer 81: 1269-1273, 1999.
21. Puzer L, Barros NM, Paschoalin T, et al: Cathepsin V, but not cathepsins L, B and K, may release angiostatin-like fragments from plasminogen. Biol Chem 389: 195-200, 2008. (Pubitemid 351170666)
22. Soff GA: Angiostatin and angiostatin-related proteins. Cancer Metastasis Rev 19: 97-107, 2000.
23. Rotenberg RG, Rozas NS, Guerri L, et al: Elevated levels of angiostatin in effusions from patients with malignant disease. Oncol Rep 11: 523-528, 2004.
24. Grebenschikov N, Geurts-Moespot A, De Witte H, et al: A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols. Int J Biol Markers 12: 6-14, 1997. (Pubitemid 27229450)
25. Span PN, Grebenchtchikov N, Geurts-Moespot J, Westphal JR, Lucassen AM and Sweep CG: EORTC Receptor and Biomarker Study Group Report: a sandwich enzyme-linked immunosorbent assay for vascular endothelial growth factor in blood and tumor tissue extracts. Int J Biol Markers 15: 184-191, 2000. (Pubitemid 30389368)
26. Murthi P, Barker G, Nowell CJ, et al: Plasminogen fragmentation and increased production of extracellular matrix-degrading proteinases are associated with serous epithelial ovarian cancer progression. Gynecol Oncol 92: 80-88, 2004. (Pubitemid 38147375)
27. Drenberg CD, Saunders BO, Wilbanks GD, et al: Urinary angiostatin levels are elevated in patients with epithelial ovarian cancer. Gynecol Oncol 117: 117-124, 2010.
28. de Witte JH, Sweep CG, Klijn JG, et al: Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer. Br J Cancer 80: 286-294, 1999.
29. de Witte JH, Sweep CG, Klijn JG, et al: Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients. Br J Cancer 79: 1190-1198, 1999.
30. Look MP, van Putten WL, Duffy MJ, et al: Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 94: 116-128, 2002. (Pubitemid 34121291)
31. Manders P, Tjan-Heijnen VC, Span PN, et al: Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer. Cancer Res 64: 659-664, 2004. (Pubitemid 38120907)
32. Manders P, Tjan-Heijnen VC, Span PN, et al: The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancer. Thromb Haemost 91: 514-521, 2004.
33. de Groot-Besseling RR, Ruers TJ, Lamers-Elemans IL, Maass CN, de Waal RM and Westphal JR: Angiostatin generating capacity and anti-tumour effects of D-penicillamine and plasminogen activators. BMC Cancer 6: 149, 2006.
34. de Groot-Besseling RR, Ruers TJ, van Kraats AA, et al: Anti-tumor activity of a combination of plasminogen activator and captopril in a human melanoma xenograft model. Int J Cancer 112: 329-334, 2004.